On July 9th 2013, Calimmune announced they had treated the first patient in a clinical trial involving the use of an innovative gene-based stem cell therapy to help protect individuals infected with HIV from the effects of the AIDS virus. Calimmune Chief Scientific Office, Geoff Symonds, PhD detailed the clinical trial procedure to the governing board of California's Stem Cell Agency (CIRM). CIRM is helping fund the trial through a CIRM Disease Team grant. A Q&A session followed Dr. Symonds presentation.
For more information, see the CIRM HIV/AIDS fact sheet